International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com,
a California-based stem cell therapeutics company, today announced that
its wholly-owned subsidiary Lifeline Cell Technology has entered into an
agreement to manufacture adipose (fat)-derived stem cell research
products for Cytori Therapeutics.
Lifeline will process and derive stem cells from adipose tissue provided
by Cytori. The manufacturing process will yield batches of frozen vials
of stem cells that have been isolated, purified and expanded from the
adipose tissue. These packaged stem cells will then move into an
international supply chain.
The cells will initially be used for research purposes for studies into
regenerative medicine and basic cell biology. Providing access and
availability of these standardized human stem cells to scientific
researchers holds the promise to accelerate discoveries and foster
advancements into new therapeutic applications.
"We are pleased that Cytori has chosen to work
with our stem cell manufacturing team to scale up and commercialize the
production of these important stem cells,"
said Jeffery Janus, President of both International Stem Cell
Corporation and Lifeline Cell Technology.
"We are in the business of providing
specialized human cells and growth media to researchers in academia, the
pharmaceutical industry, and the government. We recently reported the
launch of our first nine products and we are highly experienced in
manufacturing and selling cell and media systems,"
said Janus.
"It is a good fit for both companies,"
commented Jeff Krstich, CEO of International Stem Cell Corporation
(ISCO), "but, it is an especially important
step for ISCO. Beyond our own discoveries in stem cell research, it is
our goal to be the source of an unlimited supply of human cells for the
greater research community; thus contributing to the advance in
regenerative medicine in general, as well as participating in the
growing numbers of effective cellular therapies to treat specific
diseases.
ABOUT CYTORI THERAPEUTICS:
Cytori Therapeutics is a global leader in the development and
commercialization of regenerative medicine products. The company is
developing therapeutic applications for its Celution™
System to enable real-time regenerative cell therapy in conjunction with
breast reconstruction surgery, cardiovascular disease, and other unmet
medical needs. The Company's StemSource™ Cell
Bank, which is based on Cytori's innovative
Celution™ System, is being commercialized in
Japan to hospitals and clinics to enable regenerative cell banking. www.cytoritx.com ABOUT INTERNATIONAL STEM CELL CORPORATION:
International Stem Cell is a biotechnology company currently focused on
developing therapeutic and research products. In the area of therapeutic
product development, ISCO's objective is to create an unlimited source
of human cells for use in the treatment of several diseases, including
diabetes, liver disease and retinal disease through cell transplant
therapy. In furtherance of this objective, ISCO has developed
pluripotent human stem cells from unfertilized human eggs, and
techniques to cause those stem cells to be "differentiated" into the
specific cell types required for transplant. It has developed
manufacturing protocols to produce the cells minimizing contamination
with animal by-products, a characteristic likely to be important in
meeting U.S. Food and Drug Administration requirements. ISCO also
provides the specialized cells and growth media needed for therapeutic
cell transplantation research to academic and commercial researchers in
related fields. For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 Forward-Looking Statements Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements. |
